Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.

Waugh KA, Leach SM, Moore BL, Bruno TC, Buhrman JD, Slansky JE.

J Immunol. 2016 Aug 15;197(4):1477-88. doi: 10.4049/jimmunol.1600589. Epub 2016 Jul 1.

PMID:
27371726
2.

Control of T cell antigen reactivity via programmed TCR downregulation.

Gallegos AM, Xiong H, Leiner IM, SuĊĦac B, Glickman MS, Pamer EG, van Heijst JW.

Nat Immunol. 2016 Apr;17(4):379-86. doi: 10.1038/ni.3386. Epub 2016 Feb 22.

3.

Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens.

Hebeisen M, Allard M, Gannon PO, Schmidt J, Speiser DE, Rufer N.

Front Immunol. 2015 Nov 18;6:582. doi: 10.3389/fimmu.2015.00582. eCollection 2015. Review.

4.

T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.

Tan MP, Gerry AB, Brewer JE, Melchiori L, Bridgeman JS, Bennett AD, Pumphrey NJ, Jakobsen BK, Price DA, Ladell K, Sewell AK.

Clin Exp Immunol. 2015 May;180(2):255-70. doi: 10.1111/cei.12570.

5.

Specific increase in potency via structure-based design of a TCR.

Malecek K, Grigoryan A, Zhong S, Gu WJ, Johnson LA, Rosenberg SA, Cardozo T, Krogsgaard M.

J Immunol. 2014 Sep 1;193(5):2587-99. doi: 10.4049/jimmunol.1302344. Epub 2014 Jul 28.

6.

Accumulation of dynamic catch bonds between TCR and agonist peptide-MHC triggers T cell signaling.

Liu B, Chen W, Evavold BD, Zhu C.

Cell. 2014 Apr 10;157(2):357-68. doi: 10.1016/j.cell.2014.02.053.

7.

Computational design of the affinity and specificity of a therapeutic T cell receptor.

Pierce BG, Hellman LM, Hossain M, Singh NK, Vander Kooi CW, Weng Z, Baker BM.

PLoS Comput Biol. 2014 Feb 13;10(2):e1003478. doi: 10.1371/journal.pcbi.1003478. eCollection 2014 Feb.

8.

Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity.

Dougan SK, Dougan M, Kim J, Turner JA, Ogata S, Cho HI, Jaenisch R, Celis E, Ploegh HL.

Cancer Immunol Res. 2013 Aug;1(2):99-111. doi: 10.1158/2326-6066.CIR-13-0047.

9.

T cell avidity and tumor immunity: problems and solutions.

Hurwitz AA, Cuss SM, Stagliano KE, Zhu Z.

Cancer Microenviron. 2014 Aug;7(1-2):1-9. doi: 10.1007/s12307-013-0143-1. Epub 2013 Dec 20.

10.

2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system.

Liu B, Zhong S, Malecek K, Johnson LA, Rosenberg SA, Zhu C, Krogsgaard M.

Eur J Immunol. 2014 Jan;44(1):239-50. doi: 10.1002/eji.201343774. Epub 2013 Oct 20.

11.

Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity.

Chen S, Li Y, Depontieu FR, McMiller TL, English AM, Shabanowitz J, Kos F, Sidney J, Sette A, Rosenberg SA, Hunt DF, Mariuzza RA, Topalian SL.

J Immunol. 2013 Nov 15;191(10):5097-106. doi: 10.4049/jimmunol.1300467. Epub 2013 Oct 9.

12.

Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor.

Buhrman JD, Jordan KR, Munson DJ, Moore BL, Kappler JW, Slansky JE.

J Biol Chem. 2013 Nov 15;288(46):33213-25. doi: 10.1074/jbc.M113.509554. Epub 2013 Oct 8.

13.

Monitoring the Dynamics of T Cell Clonal Diversity Using Recombinant Peptide:MHC Technology.

Blanchfield JL, Shorter SK, Evavold BD.

Front Immunol. 2013 Jul 3;4:170. doi: 10.3389/fimmu.2013.00170. eCollection 2013.

14.

Molecular insights for optimizing T cell receptor specificity against cancer.

Hebeisen M, Oberle SG, Presotto D, Speiser DE, Zehn D, Rufer N.

Front Immunol. 2013 Jun 19;4:154. doi: 10.3389/fimmu.2013.00154. eCollection 2013.

15.

T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy.

Zhong S, Malecek K, Johnson LA, Yu Z, Vega-Saenz de Miera E, Darvishian F, McGary K, Huang K, Boyer J, Corse E, Shao Y, Rosenberg SA, Restifo NP, Osman I, Krogsgaard M.

Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6973-8. doi: 10.1073/pnas.1221609110. Epub 2013 Apr 1.

16.

SHP-1 phosphatase activity counteracts increased T cell receptor affinity.

Hebeisen M, Baitsch L, Presotto D, Baumgaertner P, Romero P, Michielin O, Speiser DE, Rufer N.

J Clin Invest. 2013 Mar;123(3):1044-56. doi: 10.1172/JCI65325. Epub 2013 Feb 8.

17.

Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.

Buhrman JD, Jordan KR, U'ren L, Sprague J, Kemmler CB, Slansky JE.

Cancer Res. 2013 Jan 1;73(1):74-85. doi: 10.1158/0008-5472.CAN-12-1005. Epub 2012 Nov 16.

18.

Improving T cell responses to modified peptides in tumor vaccines.

Buhrman JD, Slansky JE.

Immunol Res. 2013 Mar;55(1-3):34-47. doi: 10.1007/s12026-012-8348-9. Review.

19.

Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.

Irving M, Zoete V, Hebeisen M, Schmid D, Baumgartner P, Guillaume P, Romero P, Speiser D, Luescher I, Rufer N, Michielin O.

J Biol Chem. 2012 Jun 29;287(27):23068-78. doi: 10.1074/jbc.M112.357673. Epub 2012 May 1.

20.

TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines.

Jordan KR, Buhrman JD, Sprague J, Moore BL, Gao D, Kappler JW, Slansky JE.

Cancer Immunol Immunother. 2012 Oct;61(10):1627-38. Epub 2012 Feb 21.

Items per page

Supplemental Content

Write to the Help Desk